Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
13-cis-ethyl retinamide is a **synthetic retinoid derivative**, specifically the ethyl amide of 13-cis-retinoic acid (isotretinoin). It belongs to the class of retinoids, which are compounds structurally related to vitamin A and function as modulators of cell proliferation, differentiation, and apoptosis. Retinoids generally act through binding and activation of nuclear **retinoic acid receptors (RARs)** and **retinoid X receptors (RXRs)**, thereby regulating gene expression. Ethyl retinamides have been studied for their **antineoplastic** and **chemopreventive** properties in cancer models, with activity that is thought to be due to modulation of cell growth signaling and induction of cell differentiation. There is limited published information about the clinical use, development status, or commercial products containing 13-cis-ethyl retinamide. Most available data describe related compounds, such as N-(2-hydroxyethyl)retinamide (fenretinide), but not specifically 13-cis-ethyl retinamide.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 13-cis-ethyl retinamide.